13 June 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Issue of Equity

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, announces the issue of 2,466,547 new ordinary shares of £0.01 each ("Ordinary Shares") in settlement of amounts owed to a former employee of the Company ("Settlement Shares").

Admission and Total Voting Rights

Application will be made for the Settlement Shares to be admitted to trading on the London Stock Exchange's Main Market for listed securities, which is expected to occur on or around 19 June 2025 ("Admission"). The Settlement Shares will rank pari passu in all respects with the Company's existing Ordinary Shares.

Following Admission, the Company's issued share capital will comprise 157,444,030 Ordinary Shares in issue, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 157,444,030 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

Regulatory Information

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

ENDS

Enquiries:

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the immunology and oncology markets prior to securing a value accretive exit.

Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets. 

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com